ExL Pharma Presents The Pharmaceutical Managed Markets Insight & Marketing for the Pharmaceutical Industry ...(ufacturers seek to engage across all pay...)

"There are many issues and challenges biopharmaceutical marketers need to consider in today's dynamic marketplace," Jordan said. "More than ever, brand marketers must establish a clear and compelling Value Proposition for payer decision makers that supports brand positioning, and achieves favorable access and reimbursement on public and private payer formularies."

For additional information on the conference or to arrange an interview, contact Carrie Yamond at 212-367-6943 or Carrie.yamond@eurorscg.com.

About ExL Pharma:

ExL Pharma, a division of ExL Events, Inc., is an emerging leader in developing innovative, educational events that serve the healthcare community and allied professionals. Behind our diverse conference portfolio, our experienced team conducts extensive market research and targeted outreach. The results translate into innovative, high-quality conference events designed to exceed the dynamic informational needs of the healthcare community.

About Euro RSCG Life:

Euro RSCG Life aligns the company's 50 health-focused offices in 30 countries. It creates a single network with over 1,500 employees offering clients comprehensive communications disciplines, including advertising, public relations, event promotion, medical education, digital marketing, direct to patient and consulting services. The network's client roster includes GlaxoSmithKline, Novartis, Pfizer, sanofi-aventis, Schering-Plough and Wyeth. Euro RSCG Life is part of Euro RSCG Worldwide, a leading global marketing communications agency, and the largest unit of Havas, the world's fourth-largest communications group (Euronext Paris SA: HAV.Pa).

    CONTACT:
 
'/>"/>
SOURCE  Euro RSCG Life
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 
Related biology technology :

1. Hearing Scheduled in the Delaware Court of Chancery for August 27, 2007 to Establish the Valid Approval and Consummation of the Merger Between PharmAthene, Inc. and Healthcare Acquisition Corp.
2. Pharmatek Adds Cytotoxic and High-Potent Drug Development Capabilities to San Diego Laboratory
3. Vion Pharmaceuticals Pays Interest on 7.75% Convertible Senior Notes
4. Skystar Bio-Pharmaceutical Announces Second Quarter 2007 Results
5. Proceedings to Affirm Merger Between PharmAthene and Healthcare Acquisition Corp Initiated in Delaware Chancery Court
6. China Biopharmaceuticals Holdings Announces Second Quarter 2007 Financial Results
7. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
8. XTL Biopharmaceuticals Announces Financial Results for the Six Months Ended June 30, 2007
9. Dragon Pharmaceutical Reports Growth in Sales and Profits during Second Quarter of 2007
10. Cadence Pharmaceuticals Reports Second Quarter 2007 Financial Results
11. Baxa Announces 2008 Dates for STAR Center Professional Pharmacy and Cleanroom Training